NWBO Northwest Biotherapeutics Inc

  1. Stocks
  2. Healthcare
  3. OTC: NWBO

Price (delayed)

$0.7138

Market cap

$740.38M

P/E Ratio

4.2

Dividend/share

N/A

EPS

$0.17

Enterprise value

$766.9M

Highlights
The equity has soared by 74% YoY and by 24% from the previous quarter
NWBO's net income has surged by 128% year-on-year but it is down by 20% since the previous quarter
The EPS has soared by 127% YoY but it has contracted by 19% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://nwbio.com/
Peers: CLDX AMGN AGEN BMY

Key stats

What are the main financial stats of NWBO
Market
Shares outstanding
1.04B
Market cap
$740.38M
Enterprise value
$766.9M
Valuations
Price to earnings (P/E)
4.2
Price to book (P/B)
N/A
Price to sales (P/S)
582.63
EV/EBIT
5.44
EV/EBITDA
5.4
EV/Sales
623.49
Earnings
Revenue
$1.23M
EBIT
$141.05M
EBITDA
$142.09M
Free cash flow
-$50.78M
Per share
EPS
$0.17
Free cash flow per share
-$0.05
Book value per share
-$0.09
Revenue per share
$0
TBVPS
$0.03
Balance sheet
Total assets
$27.52M
Total liabilities
$119.19M
Debt
$31.35M
Equity
-$91.67M
Working capital
-$90.98M
Liquidity
Debt to equity
-0.34
Current ratio
0.07
Quick ratio
0.05
Net debt/EBITDA
0.19
Margins
EBITDA margin
11,551.7%
Gross margin
100%
Net margin
10,972.1%
Operating margin
-4,399.2%
Efficiency
Return on assets
426.5%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
11,467.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NWBO stock price

How has the Northwest Biotherapeutics stock price performed over time
Intraday
-0.86%
1 week
-2.22%
1 month
0.61%
1 year
-42.44%
YTD
1.97%
QTD
13.3%

Financial performance

How have Northwest Biotherapeutics's revenue and profit performed over time
Revenue
$1.23M
Gross profit
$1.23M
Operating income
-$54.11M
Net income
$134.96M
Gross margin
100%
Net margin
10,972.1%
NWBO's net margin has soared by 132% YoY but it is down by 24% QoQ
NWBO's net income has surged by 128% year-on-year but it is down by 20% since the previous quarter
NWBO's operating income is up by 48% YoY but it is down by 19% from the previous quarter
NWBO's operating margin is up by 41% year-on-year but it is down by 13% since the previous quarter

Growth

What is Northwest Biotherapeutics's growth rate over time

Valuation

What is Northwest Biotherapeutics stock price valuation
P/E
4.2
P/B
N/A
P/S
582.63
EV/EBIT
5.44
EV/EBITDA
5.4
EV/Sales
623.49
The EPS has soared by 127% YoY but it has contracted by 19% from the previous quarter
The equity has soared by 74% YoY and by 24% from the previous quarter
The P/S is 53% above the 5-year quarterly average of 381.0 but 4.6% below the last 4 quarters average of 609.5
Northwest Biotherapeutics's revenue has decreased by 10% YoY but it has increased by 5% QoQ

Efficiency

How efficient is Northwest Biotherapeutics business performance
The ROS has soared by 134% YoY but it has contracted by 23% from the previous quarter
The return on assets has surged by 127% year-on-year but it has declined by 19% since the previous quarter

Dividends

What is NWBO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NWBO.

Financial health

How did Northwest Biotherapeutics financials performed over time
The total assets is 77% smaller than the total liabilities
NWBO's total liabilities has dropped by 69% year-on-year and by 21% since the previous quarter
The total assets has declined by 10% since the previous quarter and by 4.3% year-on-year
NWBO's debt is 134% higher than its equity
The equity has soared by 74% YoY and by 24% from the previous quarter
NWBO's debt is up by 21% YoY but it is down by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.